← Back to Search

Protease Inhibitor

PF-07321332 for Coronavirus

Phase 2 & 3
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, days 3, 5, 10 and 14
Awards & highlights

Study Summary

This trial is testing whether or not a certain drug can help alleviate symptoms of COVID-19.

Eligible Conditions
  • Coronavirus
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, days 3, 5, 10 and 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, days 3, 5, 10 and 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28
Secondary outcome measures
Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Days 3, 5, 10 and 14
Duration of Hospitalization and Intensive Care Unit (ICU) Stay Through Day 28
Number of COVID-19 Related Medical Visits Per Day Through Day 28
+10 more

Side effects data

From 2022 Phase 2 & 3 trial • 2246 Patients • NCT04960202
6%
Dysgeusia
3%
Diarrhoea
2%
Alanine aminotransferase increased
2%
Fibrin D dimer increased
1%
Vomiting
1%
Activated partial thromboplastin time prolonged
1%
Aspartate aminotransferase increased
1%
Myalgia
1%
Headache
1%
COVID-19
1%
Dyspepsia
1%
Nausea
1%
Chills
1%
Pyrexia
1%
Creatinine renal clearance decreased
1%
Blood thyroid stimulating hormone increased
1%
COVID-19 pneumonia
1%
C-reactive protein increased
1%
Cough
1%
Dyspnoea
1%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
PF-07321332 300 mg + Ritonavir 100 mg
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-07321332/ritonavirExperimental Treatment2 Interventions
Orally administered PF-07321332+ritonavir
Group II: PlaceboPlacebo Group1 Intervention
Orally administered Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07321332
2021
Completed Phase 3
~5230
Ritonavir
2005
Completed Phase 4
~2200

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,567 Previous Clinical Trials
10,910,433 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,474 Previous Clinical Trials
8,091,601 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
Florida
How old are they?
18 - 65
What site did they apply to?
Optimus Medical Group
Advance Clinical Research Group
Omega Research Orlando, LLC
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
2021. "Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05011513.
~393 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top